請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/72902
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 吳青錫(Ching-Shyi Wu) | |
dc.contributor.author | Tsu-Wei Lin | en |
dc.contributor.author | 林祖薇 | zh_TW |
dc.date.accessioned | 2021-06-17T07:09:46Z | - |
dc.date.available | 2024-08-27 | |
dc.date.copyright | 2019-08-27 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-07-22 | |
dc.identifier.citation | 1. Jackson, S. P. and J. Bartek (2009). 'The DNA-damage response in human biology and disease.' Nature 461(7267): 1071-1078.
2. Khanna, K. K. and S. P. Jackson (2001). 'DNA double-strand breaks: signaling, repair and the cancer connection.' Nat Genet 27(3): 247-254. 3. Lieber, M. R. (2010). 'The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway.' Annu Rev Biochem 79: 181-211. 4. Krajewska, M., R. S. Fehrmann, P. M. Schoonen, S. Labib, E. G. de Vries, L. Franke and M. A. van Vugt (2015). 'ATR inhibition preferentially targets homologous recombination-deficient tumor cells.' Oncogene 34(26): 3474-3481. 5. Buisson, R., J. Niraj, A. Rodrigue, C. K. Ho, J. Kreuzer, T. K. Foo, E. J. Hardy, G. Dellaire, W. Haas, B. Xia, J. Y. Masson and L. Zou (2017). 'Coupling of Homologous Recombination and the Checkpoint by ATR.' Mol Cell 65(2): 336-346. 6. Yazinski, S. A. and L. Zou (2016). 'Functions, Regulation, and Therapeutic Implications of the ATR Checkpoint Pathway.' Annu Rev Genet 50: 155-173. 7. Jeggo, P. A., L. H. Pearl and A. M. Carr (2016). 'DNA repair, genome stability and cancer: a historical perspective.' Nat Rev Cancer 16(1): 35-42. 8. Knijnenburg, T. A., L. Wang, M. T. Zimmermann, N. Chambwe, G. F. Gao, A. D. Cherniack, H. Fan, H. Shen, G. P. Way, C. S. Greene, Y. Liu, R. Akbani, B. Feng, L. A. Donehower, C. Miller, Y. Shen, M. Karimi, H. Chen, P. Kim, P. Jia, E. Shinbrot, S. Zhang, J. Liu, H. Hu, M. H. Bailey, C. Yau, D. Wolf, Z. Zhao, J. N. Weinstein, L. Li, L. Ding, G. B. Mills, P. W. Laird, D. A. Wheeler, I. Shmulevich, R. J. Monnat, Jr., Y. Xiao and C. Wang (2018). 'Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas.' Cell Rep 23(1): 239-254.e236. 9. Kuchenbaecker, K. B., J. L. Hopper, D. R. Barnes, K. A. Phillips, T. M. Mooij, M. J. Roos-Blom, S. Jervis, F. E. van Leeuwen, R. L. Milne, N. Andrieu, D. E. Goldgar, M. B. Terry, M. A. Rookus, D. F. Easton, A. C. Antoniou, L. McGuffog, D. G. Evans, D. Barrowdale, D. Frost, J. Adlard, K. R. Ong, L. Izatt, M. Tischkowitz, R. Eeles, R. Davidson, S. Hodgson, S. Ellis, C. Nogues, C. Lasset, D. Stoppa-Lyonnet, J. P. Fricker, L. Faivre, P. Berthet, M. J. Hooning, L. E. van der Kolk, C. M. Kets, M. A. Adank, E. M. John, W. K. Chung, I. L. Andrulis, M. Southey, M. B. Daly, S. S. Buys, A. Osorio, C. Engel, K. Kast, R. K. Schmutzler, T. Caldes, A. Jakubowska, J. Simard, M. L. Friedlander, S. A. McLachlan, E. Machackova, L. Foretova, Y. Y. Tan, C. F. Singer, E. Olah, A. M. Gerdes, B. Arver and H. Olsson (2017). 'Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.' JAMA 317(23): 2402-2416. 10. Ray Chaudhuri, A. and A. Nussenzweig (2017). 'The multifaceted roles of PARP1 in DNA repair and chromatin remodelling.' Nat Rev Mol Cell Biol 18(10): 610-621. 11. Bryant, H. E., N. Schultz, H. D. Thomas, K. M. Parker, D. Flower, E. Lopez, S. Kyle, M. Meuth, N. J. Curtin and T. Helleday (2005). 'Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.' Nature 434(7035): 913-917. 12. Morris, J. R., C. Boutell, M. Keppler, R. Densham, D. Weekes, A. Alamshah, L. Butler, Y. Galanty, L. Pangon, T. Kiuchi, T. Ng and E. Solomon (2009). 'The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress.' Nature 462(7275): 886-890. 13. Schwertman, P., S. Bekker-Jensen and N. Mailand (2016). 'Regulation of DNA double-strand break repair by ubiquitin and ubiquitin-like modifiers.' Nat Rev Mol Cell Biol 17(6): 379-394. 14. Galanty, Y., R. Belotserkovskaya, J. Coates, S. Polo, K. M. Miller and S. P. Jackson (2009). 'Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks.' Nature 462(7275): 935-939. 15. Wu, C. S. and L. Zou (2016). 'The SUMO (Small Ubiquitin-like Modifier) Ligase PIAS3 Primes ATR for Checkpoint Activation.' J Biol Chem 291(1): 279-290. 16. Li, J., J. Cui, J. Zhang, Y. Liu, L. Han, C. Jia, J. Deng and H. Liang (2015). 'PIAS3, an inhibitor of STAT3, has intensively negative association with the survival of gastric cancer.' Int J Clin Exp Med 8(1): 682-689. 17. Sitarz, R., M. Skierucha, J. Mielko, G. J. A. Offerhaus, R. Maciejewski and W. P. Polkowski (2018). 'Gastric cancer: epidemiology, prevention, classification, and treatment.' Cancer Manag Res 10: 239-248. 18. Ang, T. L. and K. M. Fock (2014). 'Clinical epidemiology of gastric cancer.' Singapore Med J 55(12): 621-628. 19. Dorothy, A. S., Lacey M., Susan, K., Laura, J. H. and Rachael C. (2016) Stomach Cancer. Pennsylvania, America: National Comprehensive Cancer Network 20. TCGA (2019) TCGA dataset of PIAS3 RNA expression in different cancers https://www.proteinatlas.org/ENSG00000131788-PIAS3/pathology 21. Ghouri, Y. A., I. Mian and J. H. Rowe (2017). 'Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis.' J Carcinog 16: 1. 22. Ministry of Health and Welfare (2017) Statistics of Causes of Death https://www.mohw.gov.tw/lp-3961-2.html 23. Kluge, A., S. Dabir, I. Vlassenbroeck, R. Eisenberg and A. Dowlati (2011). 'Protein inhibitor of activated STAT3 expression in lung cancer.' Mol Oncol 5(3): 256-264. 24. Grivas, P., N. J. Vogelzang, A. S. Alva, S. Feyerabend, Y. Loriot, A. Necchi, S. Gupta, D. H. Josephs, A. Rodriguez-Vida, S. Srinivas, Y. Zakharia, K. Wride, D. Thomas, R. Dusek, A. Simmons, D. L. Nepert and S. Chowdhury (2019). 'ATLAS: A phase II open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma (mUC).' Journal of Clinical Oncology 37(7_suppl): TPS496-TPS496. 25. Golan, T., P. Hammel, M. Reni, E. Van Cutsem, T. Macarulla, M. J. Hall, J. O. Park, D. Hochhauser, D. Arnold, D. Y. Oh, A. Reinacher-Schick, G. Tortora, H. Algul, E. M. O'Reilly, D. McGuinness, K. Y. Cui, K. Schlienger, G. Y. Locker and H. L. Kindler (2019). 'Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.' N Engl J Med, 10.1056/NEJMoa1903387. 26. Schmitt, A., G. Knittel, D. Welcker, T. P. Yang, J. George, M. Nowak, U. Leeser, R. Buttner, S. Perner, M. Peifer and H. C. Reinhardt (2017). 'ATM Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung Adenocarcinoma.' Cancer Res 77(11): 3040-3056. 27. Liu, L. F., S. D. Desai, T. K. Li, Y. Mao, M. Sun and S. P. Sim (2000). 'Mechanism of action of camptothecin.' Ann N Y Acad Sci 922: 1-10. 28. Yarbro, J. W. (1992). 'Mechanism of action of hydroxyurea.' Semin Oncol 19(3 Suppl 9): 1-10. 29. Petermann, E., M. L. Orta, N. Issaeva, N. Schultz and T. Helleday (2010). 'Hydroxyurea-stalled replication forks become progressively inactivated and require two different RAD51-mediated pathways for restart and repair.' Mol Cell 37(4): 492-502. 30. Bitler, B. G., Z. L. Watson, L. J. Wheeler and K. Behbakht (2017). 'PARP inhibitors: Clinical utility and possibilities of overcoming resistance.' Gynecol Oncol 147(3): 695-704. 31. Norquist, B., K. A. Wurz, C. C. Pennil, R. Garcia, J. Gross, W. Sakai, B. Y. Karlan, T. Taniguchi and E. M. Swisher (2011). 'Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.' J Clin Oncol 29(22): 3008-3015. 32. Rottenberg, S., J. E. Jaspers, A. Kersbergen, E. van der Burg, A. O. Nygren, S. A. Zander, P. W. Derksen, M. de Bruin, J. Zevenhoven, A. Lau, R. Boulter, A. Cranston, M. J. O'Connor, N. M. Martin, P. Borst and J. Jonkers (2008). 'High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.' Proc Natl Acad Sci U S A 105(44): 17079-17084. 33. Chaudhuri, A. R., E. Callen, X. Ding, E. Gogola, A. A. Duarte, J. E. Lee, N. Wong, V. Lafarga, J. A. Calvo, N. J. Panzarino, S. John, A. Day, A. V. Crespo, B. Shen, L. M. Starnes, J. R. de Ruiter, J. A. Daniel, P. A. Konstantinopoulos, D. Cortez, S. B. Cantor, O. Fernandez-Capetillo, K. Ge, J. Jonkers, S. Rottenberg, S. K. Sharan and A. Nussenzweig (2016). 'Erratum: Replication fork stability confers chemoresistance in BRCA-deficient cells.' Nature 539(7629): 456. 34. Yazinski, S. A., V. Comaills, R. Buisson, M. M. Genois, H. D. Nguyen, C. K. Ho, T. Todorova Kwan, R. Morris, S. Lauffer, A. Nussenzweig, S. Ramaswamy, C. H. Benes, D. A. Haber, S. Maheswaran, M. J. Birrer and L. Zou (2017). 'ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.' Genes Dev 31(3): 318-332. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/72902 | - |
dc.description.abstract | 在所有DNA損傷之中,DNA的雙股斷裂是最具有傷害性的一種。同源重組 (homologous recombination, HR),一個需要ATR (ataxia telangiectasia and Rad3 related) 的過程,可以無誤的修復雙股斷裂。先前的研究中顯示PIAS3 (protein inhibitor of activated STAT 3) 不單單只是ATR-Chk1訊息傳遞路徑的調控者,更 可能參與在同源重組之中。而在最近的研究以及TCGA資料庫的分析中,顯示了PIAS3的表現量在胃癌和肝癌中特別低,因此我們提出缺乏PIAS3的胃癌和肝癌細胞可藉由抑制PARP而敏感化。Olaparib和Rucaparib,兩種用來治療BRCA缺損的卵巢癌的PARP抑制劑,在DNA損傷反應缺損的癌細胞中具有合成致死的效果,被用來測試這個假說。我們利用免疫墨點法確認了幾種胃癌和肝癌細胞的PIAS3表現低下,而細胞生存測試顯示低PIAS3表現的胃癌 (AGS, MKN45) 和肝癌細胞 (Huh-7, HepG2) 對於PARP抑制劑是敏感的。除此之外,合併使用低劑量拓撲異構酶1 (Topoisomerase I) 抑制劑在胃癌細胞上具有加成效果。免疫螢光染色法顯示Olaparib和Rucaparib在AGS和Huh-7細胞上可產生相當的DNA雙股斷裂,然而在Rucaparib處理後的細胞會從DNA雙股斷裂中回復較慢。除此之外,在異位表現PIAS3後的肝癌細胞株Huh-7可對PARP抑制劑具有抗性,可能是透過部分恢復ATR活化的功能。除了PARP抑制劑,細胞生存測試也顯示ATR抑制劑對低PIAS3表現的胃癌和肝癌細胞都是有效果的。我們的發現顯示PARP以及ATR抑制劑在PIAS3缺乏的癌症上可能具有醫療潛力。 | zh_TW |
dc.description.abstract | DNA double-strand breaks (DSBs) are the most deleterious among all types of DNA damage. Homologous recombination (HR), a process requires ATR (ataxia telangiectasia and Rad3 related), repairs DSBs flawlessly. Previous studies have shown that PIAS3 is not only a modulator of ATR-Chk1 signaling pathway but also implicated in HR. Recent studies and analyses of TCGA (The Cancer Genome Atlas) databank suggest that expression of PIAS3 is low in a remarkable fractions of both gastric and hepatic cancers. We hypothesize that gastric and hepatic cancer cells with PIAS3 deficiency can be sensitized by PARP inhibition. Olaparib and Rucaparib, two PARP inhibitors indicated for BRCA mutated ovarian cancers, are employed to test this hypothesis. Western blotting confirms that several gastric and hepatic cancer cell lines are PIAS3 deficiency. Cell viability assays show that low-PIAS3 gastric (AGS, MKN45) and hepatic cancer (Huh-7, HepG2) cells are sensitive to PARPi. In addition, combination with topoisomerase I inhibitor can have a synergistic effect in gastric cancer cells. Immunofluorescence staining reveals that Olaparib and Rucaparib induced comparable level of DNA DSBs in AGS and Huh-7 cells, however the recovery from DNA DSBs is much slower in Rucaparib treated cells. Besides, ectopically expressed PIAS3 confers resistance to PARPi in hepatic cancer cell line, Huh-7, which may be partially through the activation of ATR. Besides PARPi, viability assay also shows that ATRi is effective to both low-PIAS3 gastric and hepatic cancer. Our findings suggest that PARPi and ATRi may be potential therapeutics for treating PIAS3-deficient cancers. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T07:09:46Z (GMT). No. of bitstreams: 1 ntu-108-R06443014-1.pdf: 3377028 bytes, checksum: a3fd8c2378e382a394df91dde581fe5b (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | 口試委員會審定書 I
誌謝 II Abbreviations III 中文摘要 V Abstract VI Introduction 1 Materials and Methods 6 Results 13 Discussion 20 References 25 Figures 31 Tables 56 | |
dc.language.iso | en | |
dc.title | 缺乏PIAS3使胃癌和肝癌對PARP抑制劑敏感化的研究 | zh_TW |
dc.title | PIAS3 deficiency sensitizes gastric and hepatic cancers to PARP (poly ADP-ribose polymerase) inhibition | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 林敬哲(Jing-Jer Lin),鄧述諄(Shu-Chun Teng) | |
dc.subject.keyword | PIAS3,PARP抑制劑,胃癌,肝癌, | zh_TW |
dc.subject.keyword | PIAS3,PARP inhibitors,gastric cancer,hepatic cancer, | en |
dc.relation.page | 59 | |
dc.identifier.doi | 10.6342/NTU201901790 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2019-07-23 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥理學研究所 | zh_TW |
顯示於系所單位: | 藥理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf 目前未授權公開取用 | 3.3 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。